Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates investigation of combination therapies and their effects on tumor evolution. Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Jennifer Y., Shu, Shaokun, Kwon, Mijung, Jovanović, Bojana, Murphy, Katherine, Gulvady, Anushree, Fassl, Anne, Trinh, Anne, Kuang, Yanan, Heavey, Grace A., Luoma, Adrienne, Paweletz, Cloud, Thorner, Aaron R., Wucherpfennig, Kai W., Qi, Jun, Brown, Myles, Sicinski, Piotr, McDonald, Thomas O., Pellman, David, Michor, Franziska, Polyak, Kornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214447/
https://www.ncbi.nlm.nih.gov/pubmed/32393766
http://dx.doi.org/10.1038/s41467-020-16170-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214447/
https://www.ncbi.nlm.nih.gov/pubmed/32393766
http://dx.doi.org/10.1038/s41467-020-16170-3

Ejemplares similares